Consequently, a consortium is testing its ASO candidate IONIS-DNM2–2.5Rx (DYN101) that is administered i.v. in patients with centronuclear myopathies caused by mutations in either DNM2 or MTM1 (NCT04033159). Here, DNM2 is linked to centronuclear myopathy.